Shares of NantHealth Inc (NASDAQ:NH) rose 5.1% on Wednesday . The company traded as high as $0.92 and last traded at $0.82, approximately 409,400 shares traded hands during trading. An increase of 96% from the average daily volume of 209,344 shares. The stock had previously closed at $0.78.
NH has been the topic of a number of analyst reports. Zacks Investment Research cut shares of NantHealth from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. Cowen set a $1.00 price target on shares of NantHealth and gave the stock a “buy” rating in a report on Monday, August 26th. Finally, ValuEngine cut shares of NantHealth from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th.
The stock’s fifty day moving average price is $0.58 and its 200 day moving average price is $0.69. The company has a debt-to-equity ratio of 70.81, a current ratio of 0.75 and a quick ratio of 0.74. The stock has a market capitalization of $96.26 million, a P/E ratio of -0.52 and a beta of 1.12.
A hedge fund recently raised its stake in NantHealth stock. Miracle Mile Advisors LLC raised its position in shares of NantHealth Inc (NASDAQ:NH) by 154.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 75,000 shares of the company’s stock after buying an additional 45,500 shares during the quarter. Miracle Mile Advisors LLC owned about 0.07% of NantHealth worth $39,000 at the end of the most recent reporting period. 3.33% of the stock is currently owned by institutional investors.
About NantHealth (NASDAQ:NH)
NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.
Featured Article: Bond
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.